Wedbush Predicts Increased Earnings for Fate Therapeutics

Fate Therapeutics, Inc. (NASDAQ:FATE) – Investment analysts at Wedbush raised their Q2 2025 earnings per share (EPS) estimates for shares of Fate Therapeutics in a report issued on Tuesday, May 13th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings of ($0.36) per share for the quarter, up from their prior forecast of ($0.43). Wedbush currently has a “Neutral” rating and a $5.00 target price on the stock. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share. Wedbush also issued estimates for Fate Therapeutics’ Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.34) EPS, FY2026 earnings at ($1.09) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($1.52) EPS and FY2029 earnings at ($1.60) EPS.

Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. The business had revenue of $1.63 million during the quarter, compared to analyst estimates of $1.18 million.

A number of other analysts have also commented on FATE. Stifel Nicolaus decreased their target price on Fate Therapeutics from $5.00 to $3.00 and set a “hold” rating for the company in a research report on Thursday, March 6th. StockNews.com raised Fate Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Robert W. Baird decreased their target price on Fate Therapeutics from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Wednesday. Needham & Company LLC reaffirmed a “hold” rating on shares of Fate Therapeutics in a research report on Wednesday. Finally, Barclays decreased their target price on Fate Therapeutics from $10.00 to $2.00 and set an “overweight” rating for the company in a research report on Wednesday. Eight analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Fate Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $4.14.

Fate Therapeutics Price Performance

Shares of Fate Therapeutics stock opened at $1.07 on Friday. Fate Therapeutics has a one year low of $0.66 and a one year high of $5.92. The firm has a market capitalization of $122.63 million, a price-to-earnings ratio of -0.65 and a beta of 2.32. The business has a 50-day simple moving average of $1.01 and a 200 day simple moving average of $1.51.

Institutional Trading of Fate Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CWM LLC increased its holdings in Fate Therapeutics by 899.6% during the 1st quarter. CWM LLC now owns 41,435 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 37,290 shares in the last quarter. Graham Capital Management L.P. bought a new position in shares of Fate Therapeutics in the fourth quarter valued at approximately $37,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Fate Therapeutics in the fourth quarter valued at approximately $40,000. Brevan Howard Capital Management LP bought a new position in shares of Fate Therapeutics in the fourth quarter valued at approximately $41,000. Finally, FPC Investment Advisory Inc. bought a new position in shares of Fate Therapeutics in the fourth quarter valued at approximately $44,000. 97.54% of the stock is owned by institutional investors.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.